XML 189 R42.htm IDEA: XBRL DOCUMENT
v3.25.1

Equity (Tables) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2025 | Dec. 31, 2024
Equity (Tables) [Line Items] |  |
Schedule of Common Stock Issuable Upon Exercise of Warrants Outstanding |  | The following table summarizes the shares of the Company’s common stock issuable upon exercise of options outstanding at December 31, 2024:
Options Outstanding |  |  | Options Exercisable |
Range of Exercise Price |  |  | Number Outstanding at December 31, 2024 |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable at December 31, 2024 |  |  | Weighted Average Exercise Price |
$ | 2.93 - 31.20 |  |  |  | 20,198 |  |  |  | 3.54 |  |  | $ | 14.76 |  |  |  | 14,591 |  |  | $ | 16.38 |
| 48.75 - 123.00 |  |  |  | 20,517 |  |  |  | 2.04 |  |  |  | 78.91 |  |  |  | 20,517 |  |  |  | 78.91 |
| 154.50 - 289.50 |  |  |  | 11,764 |  |  |  | 3.44 |  |  |  | 218.21 |  |  |  | 11,764 |  |  |  | 218.21 |
$ | 2.93 - 289.50 |  |  |  | 52,479 |  |  |  | 2.93 |  |  | $ | 85.45 |  |  |  | 46,872 |  |  | $ | 94.41 |
Schedule of Stock Option Activity | Stock option activity for the three months ended March 31, 2025 was as follows:
|  | Number of Options |  |  | Weighted Average Exercise Price |
Outstanding at January 1, 2025 |  |  | 52,479 |  |  | $ | 85.45 |
Granted |  |  | 2,665 |  |  |  | 3.26 |
Expired / cancelled |  |  | (3,719 | ) |  |  | (132.47 | )
Outstanding at March 31, 2025 |  |  | 51,425 |  |  | $ | 77.79 |
Options exercisable at March 31, 2025 |  |  | 47,493 |  |  | $ | 83.97 |
Options expected to vest |  |  | 3,932 |  |  | $ | 3.13 |
Stock warrant activity for the three months ended March 31, 2025 was as follows:
|  | Number of Warrants |  |  | Weighted Average Exercise Price |
Outstanding at January 1, 2025 |  |  | 182,996 |  |  | $ | 21.37 |
Exercised |  |  | (11,833 | ) |  |  | (58.63 | )
Outstanding at March 31, 2025 |  |  | 171,163 |  |  | $ | 18.79 |
Warrants exercisable at March 31, 2025 |  |  | 91,163 |  |  | $ | 28.70 |
Warrants expected to vest |  |  | 80,000 |  |  | $ | 7.50 |
| Stock option activity for the years ended December 31, 2024 and 2023 was as follows:
|  | Number of Options |  |  | Weighted Average Exercise Price |
Outstanding at January 1, 2023 |  |  | 53,357 |  |  | $ | 195.45 |
Granted |  |  | 12,452 |  |  |  | 35.25 |
Expired |  |  | (8,929 | ) |  |  | (267.90 | )
Outstanding at December 31, 2023 |  |  | 56,880 |  |  |  | 149.03 |
Granted |  |  | 10,265 |  |  |  | 4.13 |
Expired |  |  | (14,666 | ) |  |  | (275.14 | )
Outstanding at December 31, 2024 |  |  | 52,479 |  |  | $ | 85.45 |
Options exercisable at December 31, 2024 |  |  | 46,872 |  |  | $ | 94.41 |
Options expected to vest |  |  | 5,607 |  |  | $ | 10.56 |
Stock warrant activity for the years ended December 31, 2024 and 2023 was as follows:
|  | Number of Warrants |  |  | Weighted Average Exercise Price |
Outstanding at January 1, 2023 |  |  | 8,264 |  |  | $ | 187.50 |
Issued |  |  | 34,771 |  |  |  | 48.90 |
Outstanding at December 31, 2023 |  |  | 43,035 |  |  |  | 75.53 |
Issued |  |  | 169,527 |  |  |  | 10.28 |
Cancelled (*) |  |  | (23,288 | ) |  |  | (32.85 | )
Exercised |  |  | (6,278 | ) |  |  | (50.77 | )
Outstanding at December 31, 2024 |  |  | 182,996 |  |  | $ | 21.37 |
Warrants exercisable at December 31, 2024 |  |  | 102,996 |  |  | $ | 32.13 |
Warrants expected to vest |  |  | 80,000 |  |  | $ | 7.50 |
Schedule of Nonvested Stock Options Granted | A summary of the status of the Company’s nonvested stock options granted as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:
|  | Number of Options |  |  | Weighted Average Exercise Price |
Nonvested at January 1, 2025 |  |  | 5,943 |  |  | $ | 11.54 |
Granted |  |  | 2,665 |  |  |  | 3.26 |
Cancelled |  |  | (1,853 | ) |  |  | (27.40 | )
Vested |  |  | (2,823 | ) |  |  | (5.03 | )
Nonvested at March 31, 2025 |  |  | 3,932 |  |  | $ | 3.13 |
A summary of the status of the Company’s nonvested stock warrants issued as of March 31, 2025 and changes during the three months ended March 31, 2025 is presented below:
|  | Number of Warrants |  |  | Weighted Average Exercise Price |
Nonvested at January 1, 2025 |  |  | 80,000 |  |  | $ | 7.50 |
Vested |  |  | - |  |  |  | - |
Nonvested at March 31, 2025 |  |  | 80,000 |  |  | $ | 7.50 |
| A summary of the status of the Company’s nonvested stock options granted as of December 31, 2024 and changes during the years ended December 31, 2024 and 2023 is presented below:
|  | Number of Options |  |  | Weighted Average Exercise Price |
Nonvested at January 1, 2023 |  |  | 1,334 |  |  | $ | 64.35 |
Granted |  |  | 12,452 |  |  |  | 35.25 |
Vested |  |  | (8,475 | ) |  |  | (47.14 | )
Nonvested at December 31, 2023 |  |  | 5,311 |  |  |  | 23.55 |
Granted |  |  | 10,265 |  |  |  | 4.13 |
Vested |  |  | (9,969 | ) |  |  | (10.90 | )
Nonvested at December 31, 2024 |  |  | 5,607 |  |  | $ | 10.56 |
A summary of the status of the Company’s nonvested stock warrants issued as of December 31, 2024 and changes during the years ended December 31, 2024 and 2023 was presented below:
|  | Number of Warrants |  |  | Weighted Average Exercise Price |
Nonvested at January 1, 2023 |  |  | - |  |  | $ | - |
Issued |  |  | 34,771 |  |  |  | 48.90 |
Vested |  |  | (19,560 | ) |  |  | 55.95 |
Nonvested at December 31, 2023 |  |  | 15,211 |  |  |  | 39.90 |
Issued |  |  | 169,527 |  |  |  | 10.28 |
Cancelled |  |  | (23,288 | ) |  |  | (32.85 | )
Vested |  |  | (81,450 | ) |  |  | (12.10 | )
Nonvested at December 31, 2024 |  |  | 80,000 |  |  | $ | 7.50 |
Schedule of Common Stock Issuable Upon Exercise of Options Outstanding |  | The following table summarizes the shares of the Company’s common stock issuable upon exercise of warrants outstanding at December 31, 2024:
Warrants Outstanding |  |  | Warrants Exercisable |
Range of Exercise Price |  |  |  | Number Outstanding at December 31, 2024 |  |  |  | Weighted Average Remaining Contractual Life (Years) |  |  |  | Weighted Average Exercise Price |  |  |  | Number Exercisable at December 31 , 2024 |  |  |  | Weighted Average Exercise Price |
$ | 7.50 - 37.50 |  |  |  | 165,510 |  |  |  | 4.40 |  |  | $ | 10.50 |  |  |  | 85,510 |  |  | $ | 13.31 |
| 67.50 |  |  |  | 9,222 |  |  |  | 3.40 |  |  |  | 67.50 |  |  |  | 9,222 |  |  |  | 67.50 |
| 187.50 |  |  |  | 8,264 |  |  |  | 2.30 |  |  |  | 187.50 |  |  |  | 8,264 |  |  |  | 187.50 |
$ | 7.50 - 187.50 |  |  |  | 182,996 |  |  |  | 4.25 |  |  | $ | 21.37 |  |  |  | 102,996 |  |  | $ | 32.13 |
* | Second Warrant, which was issued on May 23, 2023, July 6, 2023, October 9, 2023, and March 7, 2024, was cancelled in June 2024. Second Warrant, which was issued on June 5, 2024, is still outstanding as of December 31, 2024.
Options [Member] |  |
Equity (Tables) [Line Items] |  |
Schedule of Common Stock Issuable Upon Exercise of Options Outstanding | The following table summarizes the shares of the Company’s common stock issuable upon exercise of options outstanding at March 31, 2025:
Options Outstanding |  |  |  | Options Exercisable |
Range of Exercise Price |  |  | Number Outstanding at March 31, 2025 |  |  |  | Weighted Average Remaining Contractual Life (Years) |  |  |  | Weighted Average Exercise Price |  |  |  | Number Exercisable at March 31, 2025 |  |  |  | Weighted Average Exercise Price |
$ | 2.93 - 31.20 |  |  | 21,010 |  |  |  | 3.48 |  |  | $ | 12.19 |  |  |  | 17,078 |  |  | $ | 14.28 |
48.75 - 123.00 |  |  | 20,517 |  |  |  | 1.79 |  |  |  | 78.91 |  |  |  | 20,517 |  |  |  | 78.91 |
154.50 - 264.00 |  |  | 9,898 |  |  |  | 3.82 |  |  |  | 214.71 |  |  |  | 9,898 |  |  |  | 214.71 |
$ | 2.93 - 264.00 |  |  | 51,425 |  |  |  | 2.87 |  |  | $ | 77.79 |  |  |  | 47,493 |  |  | $ | 83.97 |
Warrants Outstanding [Member] |  |
Equity (Tables) [Line Items] |  |
Schedule of Common Stock Issuable Upon Exercise of Options Outstanding | The following table summarizes the shares of the Company’s common stock issuable upon exercise of warrants outstanding at March 31, 2025:
| Warrants Outstanding |  |  | Warrants Exercisable |
Range of Exercise Price |  | Number Outstanding at March 31, 2025 |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Weighted Average Exercise Price |  |  | Number Exercisable at March 31, 2025 |  |  | Weighted Average Exercise Price |
$ | 7.50 - 37.50 |  |  | 162,010 |  |  |  | 4.17 |  |  | $ | 9.92 |  |  |  | 82,010 |  |  | $ | 12.27 |
| 67.50 |  |  | 889 |  |  |  | 3.18 |  |  |  | 67.50 |  |  |  | 889 |  |  |  | 67.50 |
| 187.50 |  |  | 8,264 |  |  |  | 2.06 |  |  |  | 187.50 |  |  |  | 8,264 |  |  |  | 187.50 |
$ | 7.50 - 187.50 |  |  | 171,163 |  |  |  | 4.06 |  |  | $ | 18.79 |  |  |  | 91,163 |  |  | $ | 28.70 |

X
- References No definition available. + Details
Name: | avco_EquityTablesLineItems
Namespace Prefix: | avco_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the changes in outstanding nonvested shares. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AwardTypeAxis=avco_OptionsOutstandingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=avco_WarrantsOutstandingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |